Cytovance® Biologics to Expand Microbial Manufacturing
News Apr 18, 2013
In addition to its current 100L Fermenter, Cytovance recently acquired a second 100L and a 1000L Fermenter.
Applicable processing and downstream equipment upgrades to support this larger scale will also be acquired.
A facility expansion to house these new systems is currently in the planning stages. When operational, these systems will provide Cytovance's clients with the additional capacity needed to meet their program requirements.
“This increase in microbial manufacturing capacity is to meet growing customer demands for microbial fermentation services,” commented Darren Head, Cytovance President & CEO. “This marks another milestone in our contract manufacturing strategy of providing clinical material to key clients as they move though the clinic and into commercial manufacturing.”
In January, Cytovance also announced expansion to its mammalian manufacturing capabilities with the inclusion of a 5000L stainless steel bioreactor. This addition compliments the existing manufacturing process trains that include 100L, 500L and 1,000L bioreactors, 100L wave system and 50L and 200L Sartorius subs.
Cytovance continues to provide analytical method development and process development for phase I, II, and III clinical trial materials as well as regulatory expertise to support validation and commercial market launch for therapeutic proteins, recombinant proteins and monoclonal antibodies.
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Energy Drinks Pose Health Risk for YoungstersNews
In a nationwide survey of Canadian youth, over half of those who had ever consumed an energy drink had reported experiencing an adverse health event, including rapid heartbeat, nausea, and in rare cases, seizures. Currently, Canadian legislation is meant to prohibit energy drinks from being marketed to children and energy drinks are not recommend to be used by people participating in sporting activities.READ MORE
Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes SynthesisNews
TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.READ MORE